All Updates

All Updates

icon
Filter
Funding
Actuate Therapeutics announces terms for USD 50 million IPO
Precision Medicine
Jun 11, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Precision Medicine

Precision Medicine

Jun 11, 2024

Actuate Therapeutics announces terms for USD 50 million IPO

Funding

  • Actuate Therapeutics has announced the terms for its IPO, which is expected to raise USD 50 million.

  • Under the IPO, the company will offer 5.6 million shares at USD 8–10 per share. The expected use of the proceeds was undisclosed.

  • Actuate Therapeutics is a clinical-stage biotechnology company focused on developing oncology therapeutics through the inhibition of glycogen synthase kinase-3 (GSK-3). Its pipeline includes Actuate-1801, an Elragusib injection currently in clinical trials for treating refractory cancer and pancreatic cancer in adults. Other pipeline candidates include Actuate 1902, Elragusib injection for pediatric patients, and oral tablets for adult and pediatric patients with refractory cancer.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.